Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: A pooled analysis

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Jones, Paul W ^a   Donohue, James F ^b   Nedelman, Jerry ^c   Pascoe, Steve ^c   Pinault, Gregory ^c   Lassen, Cheryl ^d  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

COPD; Dyspnoea; FEV 1; Health status; Spirometry

Indexed keywords

CORTICOSTEROID; FORMOTEROL; INDACATEROL; TIOTROPIUM BROMIDE; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; QUESTIONNAIRE; AGED; CONVALESCENCE; DRUG EFFECT; EVIDENCE BASED MEDICINE; HOSPITALIZATION; LUNG; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; EVIDENCE-BASED MEDICINE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; LINEAR MODELS; LUNG; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855169766     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-161     Document Type: Article

References (32)

1. Jones PW, Agusti AGN. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:822-832. 10.1183/09031936.06.00145104, 16585091.
2. Álvarez-Gutiérrez FJ, Miravitlles M, Calle M, Gobartt E, López F, Martín A, . Grupo de Estudio EIME Impact of chronic obstructive pulmonary disease on activities of daily living: results of the EIME multicenter study. Arch Bronconeumol 2007, 43:64-72. Grupo de Estudio EIME.
3. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis 2009, 4:245-251. 2719254, 19657398.
4. de Torres JP, Cote CG, Lopez MV, Casanova C, Díaz O, Marin JM, Pinto-Plata V, de Oca MM, Nekach H, Dordelly LJ, Aguirre-Jaime A, Celli BR. Sex differences in mortality in patients with COPD. Eur Respir J 2009, 33:528-535. 10.1183/09031936.00096108, 19047315.
5. Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlösser NJ, Wouters EF, . COSMIC Study Group Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133:350-357. 10.1378/chest.07-1342, 18198263, COSMIC Study Group.
6. Gudmundsson G, Gislason T, Janson C, Lindberg E, Hallin R, Ulrik CS, Brøndum E, Nieminen MM, Aine T, Bakke P. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005, 26:414-419. 10.1183/09031936.05.00078504, 16135721.
7. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brøndum E, Nieminen MM, Aine T, Bakke P, Janson C. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006, 7:109. 10.1186/1465-9921-7-109, 1560381, 16914029.
8. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006, 61:472-477. 10.1136/thx.2005.052449, 2111202, 16517577.
9. McGlone S, Venn A, Walters EH, Wood-Baker R. Physical activity, spirometry and quality-of-life in chronic obstructive pulmonary disease. COPD 2006, 3:83-88. 10.1080/15412550600651263, 17175670.
10. Niewoehner DE, Lokhyygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, Krumpe P, Pieper K, Kesten S. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007, 131:20-28. 10.1378/chest.06-1316, 17218552.
11. Niewoehner DE. Relation of chronic obstructive pulmonary disease exacerbations to FEV1 - an intricate tango. Respiration 2009, 77:229-235. 10.1159/000162877, 18840996.
12. Omata M, Wakabayashi R, Kudoh S, Kida K. Correlation between bronchodilator responsiveness and quality of life in chronic obstructive pulmonary disease. Allergol Int 2007, 56:15-22. 10.2332/allergolint.O-06-431, 17259805.
13. Watson L, Schouten JP, Lofdahl CG, Pride NB, Laitinen LA, Postma DS, . European Respiratory Society Study on Chronic Obstructive Pulmonary Disease Predictors of COPD symptoms: does the sex of the patient matter?. Eur Respir J 2006, 28:311-318. 10.1183/09031936.06.00055805, 16707516, European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.
14. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001, 56:880-887. 10.1136/thorax.56.11.880, 1745959, 11641515.
15. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res 2011, 12:40. 10.1186/1465-9921-12-40, 3090353, 21477298.
16. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, , . on behalf of the INVOLVE (INdacaterol: Value in COPD, Longer Term Validation of Efficacy and Safety) Study Investigators Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479. 10.1136/thx.2009.125435, 20522841, on behalf of the INVOLVE (INdacaterol: Value in COPD, Longer Term Validation of Efficacy and Safety) Study Investigators.
17. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioǧlu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, . for the INHANCE Study Investigators Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162. 10.1164/rccm.200910-1500OC, 20463178, for the INHANCE Study Investigators.
18. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B, . the INLIGHT 1 study group Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010, 10:11. 10.1186/1471-2466-10-11, 2848004, 20211002, the INLIGHT 1 study group.
19. Global initiative for chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of chronic obstructive pulmonary disease. Date last updated: 2005 [http://www.goldcopd.org/Guidelines/guidelines-global-strategy-for-diagnosis-management-2005.html], Global initiative for chronic Obstructive Lung Disease (GOLD).
20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 2005, 26:319-338. 10.1183/09031936.05.00034805, 16055882.
21. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005, 2:75-79. 10.1081/COPD-200050513, 17136966.
22. Mahler DA, Witek TJ. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005, 2:99-103. 10.1081/COPD-200050666, 17136969.
23. Harrell FE. Regression modeling strategies 2001, New York: Springer-Verlag.
24. Venables WN, Ripley BD. Modern applied statistics 2002, New York: Springer-Verlag.
25. Donohue J. Minimal clinically important differences in COPD lung function. COPD 2005, 2:111-124. 10.1081/COPD-200053377, 17136971.
26. Jenkins CR, Jones PW, Calverley PMA, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10:59. 2714501, 19566934.
27. Vestbo J, Anderson JA, Calverley PMA, Celli B, Ferguson GT, Jenkins C, Yates JC, Jones PW. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J 2011, 5:44-49. 10.1111/j.1752-699X.2010.00198.x, 21159140.
28. Calverley PMA, Pauwels R, Vestbo J, Jones PW, Pride N, Gulsvick A. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. Lancet 2003, 361:449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
29. Calverley PM, Anderson JA, Celli BR, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. 10.1056/NEJMoa063070, 17314337.
30. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, . UPLIFT Study Investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554. 10.1056/NEJMoa0805800, 18836213, UPLIFT Study Investigators.
31. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003, 21:86-94. 10.1183/09031936.03.00020102, 12570114.
32. Global initiative for chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of chronic obstructive pulmonary disease. Date last updated: 2010 [http://www.goldcopd.com], Global initiative for chronic Obstructive Lung Disease (GOLD).